Acutus Medical
Insider trading & Transactions

Last updated:

Transaction Date Insider Security Shares Price per share Total value Source
Sale
HUENNEKENS R SCOTT director
Common Stock 60,000 $0.58 $34,800
Purchase
HINRICHS JAMES F. director
Common Stock 40,000 $3.78 $151,240
Purchase
BONITA DAVID P director, 10 percent owner
Common Stock 1,071,428 $14 $14,999,992
Purchase
ORBIMED ADVISORS LLC director, 10 percent owner
Common Stock 1,071,428 N/A N/A
Purchase
FLYNN JAMES E director, 10 percent owner, oth..
Common Stock 1,071,428 N/A N/A
Purchase
FLYNN JAMES E director, 10 percent owner, oth..
Common Stock 1,071,428 $14 $14,999,992
Purchase
ORBIMED ADVISORS LLC director, 10 percent owner
Common Stock 1,071,428 $14 $14,999,992
Purchase
BONITA DAVID P director, 10 percent owner
Common Stock 1,071,428 $14 $14,999,992
Purchase
FLYNN JAMES E director, 10 percent owner, oth..
Common Stock 1,500,000 $18 $27,000,000
Purchase
ORBIMED ADVISORS LLC director, 10 percent owner
Common Stock 415,000 $18 $7,470,000
Purchase
BARNICKEL JOHN officer: Chief Commercial Officer
Common Stock 7,300 $18 $131,400
Purchase
FLYNN JAMES E director, 10 percent owner, oth..
Common Stock 1,500,000 $18 $27,000,000
Purchase
HINRICHS JAMES F. director
Common Stock 10,000 $18 $180,000
Purchase
ORBIMED ADVISORS LLC director, 10 percent owner
Common Stock 415,000 $18 $7,470,000
Purchase
BONITA DAVID P director, 10 percent owner
Common Stock 415,000 $18 $7,470,000

Showing 1 to 15 of 15 results.

Insider trading

Monitoring trades made by the management members or major shareholders of companies may help create a sharper picture of what is happening inside the companies. Base your decisions on buys or sells of the people involved and do the right thing at the right time.

Who is insider?

Every director or senior officer, as well as any other entity or individual owning more than 10% of the company’s shares on the stock market, is called an insider. Such people or entities are allowed to buy/sell the company's shares under strictly controlled conditions. Key premise here is that none of them can make trades based on non-public information about the company.